Sinclair Research poaches Covance, Lilly veteran Wakefield

Research
(Image: AstraZeneca)

Preclinical contract research organization Sinclair Research has carved out a new role for G. Alex Wakefield as he becomes its vice president of research and operations.

Here, the former Covance and Eli Lilly executive will have overall responsibility for the company’s research services and its operational processes, while also being charged with “driving the growth of Sinclair’s business model and fostering positive relationships with new and current customers,” according a company statement.

Sinclair offers animal efficacy models, IND-enabling toxicology services and research capabilities to biopharma, animal health and medical device companies.

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

“Alex’s combination of experience across pharma and CRO services coupled with his scientific knowledge of both efficacy and safety animal modeling will enable Sinclair to move to the next level in size, scope and market leadership,” said Guy Bouchard, Sinclair president.

“2017 was an outstanding year for Sinclair Research, particularly related to GLP services and regulatory compliance. As a seasoned industry executive, Alex’s proven leadership skills will be invaluable as we continue to grow our business.”

Suggested Articles

There are thousands of clinical trials ongoing around the world, but only a small percentage of patients participate. Icon is hoping to change that.

Ginkgo Bioworks is buying Warp Drive Bio’s genome mining team, tech and database, eyeing the platform for use in next-gen antibiotics.

To make clinical trials more affordable and lead to the results needed for approval, MarkLogic has set up a new hub designed to do just that.